



COVID-19 VACCINE UPDATES

August 29, 2024

Before We Start

- All participants will be muted for the presentation.
- You may ask questions using the Q&A box, and questions will be answered at the end of the presentation.
- Continuing education is available for nurses and medical assistants.
- If you're watching in a group setting and wish to claim CE credit, please make sure you register for the webinar and complete the evaluation as an individual.
- You can find more information here: <https://doh.wa.gov/you-and-your-family/immunization/immunization-training/covid-19-august-29-2024>

Continuing Education

- This nursing continuing professional development activity was approved by Montana Nurses Association, an accredited approver with distinction by the American Nurses Credentialing Center's Commission on Accreditation. Upon successful completion of this activity, 1.0 contact hours will be awarded.
- This program has been granted prior approval by the American Association of Medical Assistants (AAMA) for 1.0 administrative continuing education unit.

Disclosures

The planners and speakers of this activity have no relevant financial relationships with any commercial interests pertaining to this activity.

Learning Objectives

- Understand the COVID-19 vaccine recommendations for 2024-2025.
- Describe vaccine ordering and availability through the WA DOH Childhood and Adult Vaccine Programs.
- Discuss current COVID-19 vaccine storage and handling guidelines.


Presenters from the WA Department of Health

Heidi Kelly, MS, RN-BC
Public Health Nurse Consultant

Elizabeth Parrish
Vaccine Assurance Coordinator

2024-2025 COVID-19 Vaccine Recommendations

HEIDI KELLY MS, RN-BC



COVID-19 Vaccine Recommendations

Everyone 6mos and older is recommended to receive an updated 2024-2025 COVID-19 vaccine dose appropriate for their age.

2024-2025 COVID-19 Vaccines



- mRNA
- Omicron JN.1-lineage of SARS-CoV-2, KP.2
- Moderna COVID-19 Vaccine
- SPIKEVAX



- mRNA
- Omicron JN.1-lineage of SARS-CoV-2, KP.2
- Pfizer-BioNTech COVID-19 Vaccine
- Comirnaty

Awaiting Authorization

The Novavax logo, featuring the word "novavax" in a dark blue, lowercase, sans-serif font. Below it is the tagline "Inventing tomorrow's vaccines today." To the right of the text is a circular graphic composed of small dots in blue and orange.

- Protein Subunit
- Omicron JN.1 variant of SARS-CoV-2
- Approved for 12 and up

COVID-19 vaccine recommendations for those not moderately or severely immunocompromised



COVID-19 vaccination guidance for people who are not moderately or severely immunocompromised

6mos-4 years old

COVID-19 vaccination history	2024–2025 vaccine	Number of 2024–2025 vaccine doses indicated	Dosage (mL/ug)	Interval between doses
Unvaccinated	Moderna	2	0.25 mL/25 ug	Dose 1: Day 0 Dose 2: 4–8 weeks after Dose 1*
	OR			
	Pfizer-BioNTech	3	0.3 mL/3 ug	Dose 1: Day 0 Dose 2: 3–8 weeks after Dose 1* Dose 3: At least 8 weeks after Dose 2
1 dose any Moderna	Moderna	1	0.25 mL/25 ug	Dose 2: 4–8 weeks after Dose 1*
2 or more doses any Moderna NOT including at least 1 dose 2024–2025 Moderna	Moderna	1	0.25 mL/25 ug	At least 8 weeks after last dose
2 or more doses any Moderna INCLUDING at least 1 dose 2024–2025 Moderna	No further doses indicated			
1 dose any Pfizer-BioNTech	Pfizer-BioNTech	2	0.3 mL/3 ug	Dose 2: 3–8 weeks after Dose 1* Dose 3: At least 8 weeks after Dose 2
2 doses any Pfizer-BioNTech	Pfizer-BioNTech	1	0.3 mL/3 ug	Dose 3: At least 8 weeks after Dose 2
3 or more doses any Pfizer-BioNTech NOT including at least 1 dose 2024–2025 Pfizer-BioNTech	Pfizer-BioNTech	1	0.3 mL/3 ug	At least 8 weeks after last dose
3 or more doses any Pfizer-BioNTech INCLUDING at least 1 dose 2024–2025 Pfizer-BioNTech	No further doses indicated			

Source: <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#covid-vaccine>

Children transitioning from 4 years to 5 during initial vaccination series

Children who transition from age 4 years to age 5 years during the initial vaccination series should receive 1 dose of vaccine from the same manufacturer using the dosage for children ages 5–11 years on or after turning age 5 years:

- **Moderna:** 1 dose of 2024–2025 Moderna (0.25 mL/25 ug) 4-8 weeks after the first dose; there is no dosage change.
- **Pfizer-BioNTech:** 1 dose of 2024–2025 Pfizer-BioNTech (0.3 mL/10 ug). If the 10 ug dose is the second dose, administer 3–8 weeks after the first dose; if it is the third dose, administer at least 8 weeks after the second dose.

COVID-19 vaccination guidance for people who are not moderately or severely immunocompromised

Ages 5-11 years

COVID-19 vaccination history	2024–2025 vaccine	Number of 2024–2025 doses indicated	Dosage (mL/ug)	Interval between doses
Unvaccinated	Moderna	1	0.25 mL/25 ug	—
	OR			
1 or more doses any mRNA NOT including 1 dose any 2024–2025 mRNA vaccine	Pfizer-BioNTech	1	0.3 mL/10 ug	—
	OR			
1 or more doses any mRNA, INCLUDING 1 dose 2024–2025 mRNA vaccine	Moderna	1	0.25 mL/25 ug	At least 8 weeks after last dose
	OR			
1 or more doses any mRNA, INCLUDING 1 dose 2024–2025 mRNA vaccine	Pfizer-BioNTech	1	0.3 mL/10 ug	At least 8 weeks after last dose
	No further doses indicated			

Source: <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#covid-vaccine>

COVID-19 vaccination guidance for people who are not moderately or severely immunocompromised

Ages 12 years and up

COVID-19 vaccination history	2024–2025 vaccine	Number of 2024–2025 doses indicated	Dosage (mL/ug)	Interval between doses
Unvaccinated	Moderna	1	0.5 mL/50 ug	—
	OR			
1 or more doses any mRNA, NOT including 1 dose any 2024–2025 mRNA vaccine	Pfizer-BioNTech	1	0.3 mL/30 ug	—
	OR			
1 or more doses any mRNA, INCLUDING 1 dose any 2024–2025 mRNA vaccine	Moderna	1	0.5 mL/50 ug	At least 8 weeks after last dose
	OR			
1 or more doses any Novavax, NOT including 1 dose any 2024–2025 mRNA vaccine	Pfizer-BioNTech	1	0.3 mL/30 ug	At least 8 weeks after last dose
	OR			
1 or more doses any mRNA, INCLUDING 1 dose any 2024–2025 mRNA vaccine	No further doses indicated			
1 or more doses any Novavax, NOT including 1 dose any 2024–2025 mRNA vaccine	Moderna	1	0.5 mL/50 ug	At least 8 weeks after last dose
	OR			
1 or more doses any Novavax, NOT including 1 dose any 2024–2025 mRNA vaccine	Pfizer-BioNTech	1	0.3 mL/30 ug	At least 8 weeks after last dose
	OR			

NOTE:

- **People ages 65 years and older:** An additional dose of 2024–2025 COVID-19 vaccine is not currently recommended.

Source: <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#covid-vaccine>

Knowledge Check

A 24 year old healthy patient arrives to the clinic requesting a 2024-2025 COVID-19 vaccine. They have never received a COVID-19 vaccine before but are now starting a job that requires it. How many doses of COVID-19 vaccine will they require to be up-to-date?

- A. 1 dose of either Moderna or Pfizer BioNTech 2024-25 COVID-19 vaccine
- B. 2 doses of Moderna or Pfizer BioNTech 2024-25 COVID-19 vaccine separated by at least 4 weeks
- C. 2 doses of Moderna or 3 doses of Pfizer BioNTech 2024-25 COVID-19 vaccine
- D. None of the above

Knowledge Check Answer


A. 1 dose of either Moderna or Pfizer BioNTech 2024-25 COVID-19 vaccine

Ages 12 years and up

COVID-19 vaccination history	2024–2025 vaccine	Number of 2024–2025 doses indicated	Dosage (mL/ug)	Interval between doses
Unvaccinated	Moderna	1	0.5 mL/50 ug	—
	OR			
	Pfizer-BioNTech	1	0.3 mL/30 ug	—

Source: <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html# covid-vaccine>

COVID-19 vaccine recommendations for those who are moderately or severely immunocompromised



COVID-19 vaccination guidance for people who are moderately or severely immunocompromised including additional doses

6mos-4 years old

COVID-19 vaccination history	2024–2025 vaccine	Number of 2024–2025 doses indicated	Dosage (mL/ug)	Interval between doses
Unvaccinated	Moderna	3	0.25 mL/25 ug	Dose 1: Day 0 Dose 2: 4 weeks after Dose 1 Dose 3: At least 4 weeks after Dose 2 See additional doses
	OR			
	Pfizer-BioNTech	3	0.3 mL/3 ug	Dose 1: Day 0 Dose 2: 3 weeks after Dose 1 Dose 3: At least 8 weeks after Dose 2 See additional doses
1 dose any Moderna	Moderna	2	0.25 mL/25 ug	Dose 2: 4 weeks after Dose 1 Dose 3: At least 4 weeks after Dose 2 See additional doses
2 doses any Moderna	Moderna	1	0.25 mL/25 ug	Dose 3: At least 4 weeks after Dose 2 See additional doses
3 or more doses any Moderna NOT including at least 1 dose 2024–2025 Moderna	Moderna	1	0.25 mL/25 ug	At least 8 weeks after last dose See additional doses
3 or more doses any Moderna INCLUDING at least 1 dose 2024–2025 Moderna	See additional doses			

Source: <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#covid-vaccine>

COVID-19 vaccination guidance for people who are moderately or severely immunocompromised including additional doses

6mos-4 years old

COVID-19 vaccination history	2024–2025 vaccine	Number of 2024–2025 doses indicated	Dosage (mL/ug)	Interval between doses
1 dose any Pfizer-BioNTech	Pfizer-BioNTech	2	0.3 mL/3 ug	Dose 2: 3 weeks after Dose 1 Dose 3: At least 8 weeks after Dose 2 See additional doses
2 doses any Pfizer-BioNTech	Pfizer-BioNTech	1	0.3 mL/3 ug	Dose 3: At least 8 weeks after Dose 2 See additional doses
3 or more doses any Pfizer-BioNTech NOT including at least 1 dose 2024–2025 Pfizer-BioNTech	Pfizer-BioNTech	1	0.3 mL/3 ug	At least 8 weeks after last dose See additional doses
3 or more doses any Pfizer-BioNTech INCLUDING at least 1 dose 2024–2025 Pfizer-BioNTech	See additional doses			

Source: <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#covid-vaccine>

COVID-19 vaccination guidance for people who are moderately or severely immunocompromised including additional doses

ADDITIONAL DOSES:

- Children 6mo to 4 years may receive 1 additional dose of 2024–2025 mRNA COVID-19 vaccine from the same manufacturer as the initial series at least 2 months after the last 2024–2025 mRNA vaccine dose.
- Further additional 2024–2025 mRNA dose(s) may be administered from the same manufacturer, informed by the clinical judgment of a healthcare provider and personal preference and circumstances.
- Any further additional doses should be administered at least 2 months after the last 2024–2025 mRNA vaccine dose

Source: <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#vaccine>

COVID-19 vaccination guidance for people who are moderately or severely immunocompromised including additional doses

Ages 5-11 years

COVID-19 vaccination history	2024-2025 vaccine	Number of 2024-2025 doses indicated	Dosage (mL/ug)	Interval between doses
Unvaccinated	Moderna	3	0.25 mL/25 ug	Dose 1: Day 0 Dose 2: 4 weeks after Dose 1 Dose 3: At least 4 weeks after Dose 2 See additional doses
	OR			
	Pfizer-BioNTech	3	0.3 mL/10 ug	Dose 1: Day 0 Dose 2: 3 weeks after Dose 1 Dose 3: At least 4 weeks after Dose 2 See additional doses
1 dose any Moderna	Moderna	2	0.25 mL/25 ug	Dose 2: 4 weeks after Dose 1 Dose 3: At least 4 weeks after Dose 2 See additional doses
2 doses any Moderna	Moderna	1	0.25 mL/25 ug	Dose 3: At least 4 weeks after Dose 2 See additional doses

Source: <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#covid-vaccine>

COVID-19 vaccination guidance for people who are moderately or severely immunocompromised including additional doses

Ages 5-11 years

COVID-19 vaccination history	2024-2025 vaccine	Number of 2024-2025 doses indicated	Dosage (mL/ug)	Interval between doses
1 dose any Pfizer-BioNTech	Pfizer-BioNTech	2	0.3 mL/10 ug	Dose 2: 3 weeks after Dose 1 Dose 3: At least 4 weeks after Dose 2 See additional doses
2 doses any Pfizer-BioNTech	Pfizer-BioNTech	1	0.3 mL/10 ug	Dose 3: At least 4 weeks after Dose 2 See additional doses
3 or more doses any Moderna or 3 or more doses any Pfizer-BioNTech NOT including at least 1 dose any 2024–2025 mRNA vaccine†	Moderna	1	0.25 mL/25 ug	At least 8 weeks after last dose See additional doses
	OR			
	Pfizer-BioNTech	1	0.3 mL/10 ug	At least 8 weeks after last dose See additional doses
3 or more doses any mRNA vaccine INCLUDING at least 1 dose any 2024–2025 mRNA vaccine	See additional doses			

Source: <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#covid-vaccine>

Children transitioning from 4 years to 5 during initial vaccination series

Children who transition from age 4 years to age 5 years during the initial vaccination series should complete the 3-dose series using the dosage for children ages 5–11 years for all doses received on or after turning age 5 years:

- **Moderna series:** 2024–2025 Moderna, 0.25 mL/25 ug; there is no dosage change
- **Pfizer-BioNTech series:** 2024–2025 Pfizer-BioNTech, 0.3 mL/10 ug

This COVID-19 vaccine history refers to previous receipt of 3 doses of mRNA vaccine from the same manufacturer (i.e., Moderna or Pfizer-BioNTech) for initial vaccination followed by 1 or more additional doses of either Moderna or Pfizer-BioNTech, excluding receipt of 2024–2025 mRNA vaccine for any previous doses.

COVID-19 vaccination guidance for people who are moderately or severely immunocompromised including additional doses

Ages 12 years and up

COVID-19 vaccination history	Updated 2024-2025 vaccine	Number of 2024-2025 doses indicated	Dosage (mL/ug)	Interval between doses
Unvaccinated	Moderna	3	0.5 mL/50 ug	Dose 1: Day 0 Dose 2: 4 weeks after Dose 1 Dose 3: At least 4 weeks after Dose 2 See additional doses
	OR			
	Pfizer-BioNTech	3	0.3 mL/30 ug	Dose 1: Day 0 Dose 2: 3 weeks after Dose 1 Dose 3: At least 4 weeks after Dose 2 See additional doses
1 dose any Moderna	Moderna	2	0.5 mL/50 ug	Dose 2: 4 weeks after Dose 1 Dose 3: At least 4 weeks after Dose 2 See additional doses
2 doses any Moderna	Moderna	1	0.5 mL/50 ug	Dose 3: At least 4 weeks after Dose 2 See additional doses

Source: <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#covid-vaccine>

COVID-19 vaccination guidance for people who are moderately or severely immunocompromised including additional doses

Ages 12 years and up

COVID-19 vaccination history	Updated 2024-2025 vaccine	Number of 2024-2025 doses indicated	Dosage (mL/ug)	Interval between doses
1 dose any Pfizer-BioNTech	Pfizer-BioNTech	2	0.3 mL/30 ug	Dose 2: 3 weeks after Dose 1 Dose 3: At least 4 weeks after Dose 2 See additional doses
2 doses any Pfizer-BioNTech	Pfizer-BioNTech	1	0.3 mL/30 ug	Dose 3: At least 4 weeks after Dose 2 See additional doses
3 or more doses any Moderna or 3 or more doses any Pfizer-BioNTech NOT including at least 1 dose any mRNA 2024–2025 vaccine†	Moderna	1	0.5 mL/50 ug	At least 8 weeks after last dose See additional doses
	OR			
	Pfizer-BioNTech	1	0.3 mL/30 ug	At least 8 weeks after last dose See additional doses
3 or more doses any mRNA vaccine INCLUDING at least 1 dose any 2024–2025 vaccine	See additional doses			
1 or more doses any Novavax NOT including 1 dose any 2024–2025 mRNA vaccine	Moderna	1	0.5 mL/50 ug	At least 8 weeks after last dose See additional doses
	OR			
	Pfizer-BioNTech	1	0.3 mL/30 ug	At least 8 weeks after last dose See additional doses

Source: <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#covid-vaccine>

Children Transitioning from 11 to 12 years

Children who transition from age 11 years to age 12 years during the initial vaccination series should complete the 3-dose series using the dosage for people ages 12 years and older for all doses received on or after turning age 12 years:

- **Moderna series:** 2024–2025 Moderna, 0.5 mL/50ug
- **Pfizer-BioNTech series:** 2024–2025 Pfizer-BioNTech, 0.3 mL/30 ug

Additional Doses

- Moderately or severely immunocompromised individuals ages 5 and up may receive 1 additional dose of 2024–2025 mRNA COVID-19 vaccine (i.e., either Moderna or Pfizer-BioNTech, regardless of the manufacturer for the initial series) at least 2 months following the last recommended 2024–2025 vaccine dose.
- Further additional doses may be administered, informed by the clinical judgment of a healthcare provider and personal preference and circumstances. Any further additional doses should be administered at least 2 months after the last 2024–2025 COVID-19 vaccine dose.

Source: <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#vaccine>

Mixed initial series

If mRNA vaccine doses are administered from different manufacturers a 3-dose schedule should be followed:

- *Children ages 6 months–4 years*
 - The second dose is administered 4–8 weeks after the first dose.
 - The third dose of either 2024–2025 Moderna vaccine or 2024–2025 Pfizer-BioNTech vaccine is administered at least 8 weeks after the second dose.
- *People ages 6 months and older who are moderately or severely immunocompromised*
 - The second dose is administered 4 weeks after the first dose.
 - The third dose of either 2024–2025 Moderna vaccine or 2024–2025 Pfizer-BioNTech vaccine is administered as follows:
 - Ages 6 months–4 years: at least 8 weeks after the second dose
 - Ages 5 years and older: at least 4 weeks after the second dose

SOURCE: <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#Interchangeability>

Knowledge Check

A parent brings in an immunocompromised 4 year old child asking for an additional dose of 2024-25 COVID-19 vaccine. The child completed a primary series of Pfizer-BioNTech vaccine last year and received their 2024-25 Pfizer-BioNTech COVID-19 vaccine dose 9 weeks ago. What is the best response to this request?

- a. The child is not eligible for a dose at this time, they have received their 2024-2025 COVID-19 dose already.
- b. Administer one dose of 2024-25 Pfizer-BioNTech COVID-19 vaccine, it has been at least 8 weeks since their last dose.
- c. Ask the parent why they think their child needs another dose and provide based on their answer.
- d. Administer one dose of 2024-25 Moderna COVID-19 vaccine, it has been at least 8 weeks since their last dose.

Knowledge Check Answer

b. Administer one dose of 2024-25 Pfizer BioNTech COVID-19 vaccine, it has been at least 8 weeks since their last dose.

Ages 6 months–4 years

COVID-19 vaccination history	2024–2025 vaccine	Number of 2024–2025 doses indicated	Dosage (mL/ug)	Interval between doses
3 or more doses any Pfizer-BioNTech NOT including at least 1 dose 2024–2025 Pfizer-BioNTech	Pfizer-BioNTech	1	0.3 mL/3 ug	At least 8 weeks after last dose See additional doses
3 or more doses any Pfizer-BioNTech INCLUDING at least 1 dose 2024–2025 Pfizer-BioNTech	See additional doses			
ADDITIONAL DOSES: Children in this age group may receive 1 additional dose of 2024–2025 mRNA COVID-19 vaccine from the same manufacturer as the initial series at least 2 months after the last 2024–2025 mRNA vaccine dose indicated in the table. Further additional 2024–2025 mRNA dose(s) may be administered from the same manufacturer, informed by the clinical judgment of a healthcare provider and personal preference and circumstances. Any further additional doses should be administered at least 2 months after the last 2024–2025 mRNA vaccine dose.				

Source: <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html# covid-vaccine>

COVID-19 vaccination and prior SARS-CoV-2 infection

- People who recently had SARS-CoV-2 infection may consider delaying a COVID-19 vaccine dose by 3 months from symptom onset or positive test (if infection was asymptomatic).
- Studies have shown that increased time between infection and vaccination might result in an improved immune response to vaccination.
- Also, a low risk of reinfection has generally been observed in the months following infection.
- Individual factors such as risk of COVID-19 severe disease and current indicators of community transmission should be taken into account when determining whether to delay getting a COVID-19 vaccination after infection.

Source: <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#covid-vaccine>

Vaccine administration errors and deviations

For all vaccine administration errors:

- Inform the recipient of the vaccine administration error.
- Consult with the [jurisdiction immunization program](#) and/or [immunization information system \(IIS\)](#) to determine how the dose should be entered into the IIS.
- Determine how the error occurred and implement strategies to prevent it from happening again.
- Follow the revaccination guidance in the [table under Appendix B](#) of the Interim Considerations for use of COVID-19 vaccine webpage, using an age-appropriate COVID-19 vaccine product. Then continue with the recommended schedule for subsequent dose(s) unless otherwise noted in the Table.

**Vaccinators should consult [Reporting of vaccine adverse events](#) for information on reporting to the Vaccine Adverse Event Reporting System (VAERS) after COVID-19 vaccination. To file an electronic report, see the [VAERS website](#).

Slide resources:

<https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us-appendix.html#appendix-b>

<https://www.cdc.gov/vaccines/hcp/admin/admin-protocols.html>

<https://www.cdc.gov/pinkbook/hcp/table-of-contents/index.html>

Additional Resources



- <https://www.hhs.gov/risk-less-do-more/index.html>



- Fostering a Culture of Immunization in Your Practice
<https://www.train.org/main/course/1121648/details>

American Academy
of Pediatrics



DEDICATED TO THE HEALTH OF ALL CHILDREN®

- [Reminder and Recall Strategies \(aap.org\)](#)
- [Communicating With Families About How to Protect Against Fall and Winter Respiratory Viruses \(aap.org\)](#)
- [COVID-19 Vaccine for Children \(aap.org\)](#)
- [COVID Vaccine Dosing_Quick Reference.pdf \(aap.org\)](#)



- [Strategies for Increasing Adult Vaccination Rates | Adult Vaccines | CDC](#)
- [Reminder Systems and Strategies for Increasing Childhood Vaccination Rates | CDC](#)



- [COVID-19 | Immunize.org](#)
- [Ask The Experts About Vaccines: COVID-19 | Immunize.org](#)



[Promising Practices to Improve Pediatric COVID-19 Immunization Rates Toolkit](#)

VAERS

Vaccine Adverse Event Reporting System



Co-Managed by
CDC and FDA

A screenshot of the VAERS website homepage. At the top left is the VAERS logo and the text 'Vaccine Adverse Event Reporting System' with the URL 'www.vaers.hhs.gov'. A navigation bar contains links for 'About VAERS', 'Report an Adverse Event', 'VAERS Data', 'Resources', and 'Submit Follow-Up Information'. The main content area features a question in English: 'Have you had a reaction following a vaccination?' with two numbered steps: '1. Contact your healthcare provider.' and '2. Report an Adverse Event using the VAERS online form or the new downloadable PDF. **New!**'. Below this is a blue-bordered box with an 'Important' notice: 'If you are experiencing a medical emergency, seek immediate assistance from a healthcare provider or call 9-1-1. CDC and FDA do not provide individual medical treatment, advice, or diagnosis. If you need individual medical or health care advice, consult a qualified healthcare provider.' This is followed by the same question in Spanish: '¿Ha tenido una reacción después de recibir una vacuna?' with corresponding steps in Spanish. To the right is a photograph of a family (father, mother, and two children) looking at a laptop. Below the photo is a light blue box with the text 'What is VAERS?'. At the bottom, there are four white boxes with blue headers and light blue backgrounds, each with an image and a description: 'REPORT AN ADVERSE EVENT' (with an image of a doctor and patient), 'SEARCH VAERS DATA' (with an image of hands using a tablet), 'REVIEW RESOURCES' (with an image of a woman reading), and 'SUBMIT FOLLOW-UP INFORMATION' (with an image of a woman at a computer).

<http://vaers.hhs.gov>

SOURCE: <https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2024-06-26-28/04-COVID-Duffy-508.pdf>

V-SAFE

- V-safe is a vaccine safety monitoring system that lets you share with CDC how you or your dependent feel after getting a COVID-19 or RSV vaccine.
- Your participation in V-safe helps CDC monitor the safety of select vaccines.
- V-safe is one of several systems CDC uses to closely monitor the safety of vaccines in the United States.






SOURCE: https://www.cdc.gov/vaccine-safety-systems/v-safe/?CDC_AAref_Val=https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/v-safe/index.html

COVID-19 STORAGE & HANDLING



ELIZABETH PARRISH

COVID-19 Vaccines Supplied Through the Childhood Vaccine Program (CVP)

Pfizer:

Infant/Toddler 6 months-4 years	Pediatric 5-11 years	Adolescent 12+/Adult Pre-Filled Syringe
		 Pink Label
2024-2025 Formula	2024-2025 Formula	2024-2025 Formula

Moderna:

Pediatric 6 months-11 years Pre-filled syringe	Adolescent 12+/Adult Pre-Filled Syringe
 Green Label	 Blue Label
2024-2025 Formula	2024-2025 Formula

Novavax

(Pending FDA Authorization)

Adolescent 12+/Adult
Pre-Filled Syringe




2024-2025 Formula

COVID-19 Vaccines Supplied Through the Adult Vaccine Program (AVP)

Pfizer:


Adolescent 12+/Adult Pre-Filled Syringe
 Pink Label
2024-2025 Formula

Moderna:

Adolescent 12+/Adult Pre-Filled Syringe
 Blue Label
2024-2025 Formula

Novavax:







(Pending FDA Authorization)

Adolescent 12+/Adult Pre-Filled Syringe

2024-2025 Formula

COVID-19 Vaccines At-a- Glance



2024-2025 STATE SUPPLIED COVID-19 VACCINES AT-A-GLANCE

Characteristics	Pfizer-BioNTech Adolescent/Adult (Comirnaty) Single-dose Prefilled Syringe	Pfizer-BioNTech Pediatric/Infant Multi-dose Vial	Pfizer-BioNTech Pediatric Single-dose Vial	Moderna Adolescent/Adult (Spikevax) Single-dose Prefilled Syringe	Moderna Pediatric Single-dose Prefilled Syringe	Novavax* Single-Dose Prefilled Syringe *Pending FDA authorization
Vial Cap/Label Color	 Pink stripe on box indicating "DO NOT FREEZE"	 Yellow Cap	 Blue Cap	 Blue Label on box	 Green Label on box	
Amount of Diluent	NO DILUTION	1.1 mL	NO DILUTION	NO DILUTION	NO DILUTION	NO DILUTION
Formulation	Each prefilled syringe contains 1 dose of 0.3 mL	Each multidose vial contains 3 doses of 0.3 mL	Each vial contains 1 dose of 0.3 mL	Each syringe contains 1 dose of 0.5 mL	Each syringe contains 1 dose of 0.25 mL	*Each syringe contains 1 dose of 0.5 mL
Manufacturer	Pfizer BioNTech	Pfizer BioNTech	Pfizer BioNTech	Moderna	Moderna	Novavax
CPT/CVX Codes	91320 / 309	91318 / 308	91319 / 310	91322 / 312	91321 / 311	*91304 / 313
NDC Number	00069-2432-10	59267-4426-02	59267-4438-02	80777-0110-93	80777-0291-80	*80631-0107-10
Age – Licensure	12+ years	6 months-4 years	5-11 years	12+ years	6 months-11 years	12+ years
Storage: Unpunctured Vials Freezer	DO NOT STORE IN REGULAR FREEZER	DO NOT STORE IN REGULAR FREEZER	DO NOT STORE IN REGULAR FREEZER	-50°C and -15°C (-58°F and 5°F) until expiration date	-50°C and -15°C (-58°F and 5°F) until expiration date	DO NOT FREEZE
Storage: Unpunctured Vials Ultracold Freezer	DO NOT STORE IN ULTRA-COLD FREEZER	-90°C and -60°C (-130°F and -76°F) up to 18 months	-90°C and -60°C (-130°F and -76°F) up to 18 months	N/A	N/A	N/A
Storage: Unpunctured Vials/Prefilled Syringes Refrigerator	2°C to 8°C (36°F to 46°F) until expiration	2°C and 8°C (36°F and 46°F) up to 10 weeks	2°C and 8°C (36°F and 46°F) up to 10 weeks	2°C and 8°C (36°F and 46°F) up to 60 days	2°C and 8°C (36°F and 46°F) up to 60 days	2°C to 8°C (36°F to 46°F) <u>up to 9 months</u>
Storage: Unpunctured Vials Room Temp	N/A	8°C and 25°C (46°F and 77°F) up to 12 hours prior to first puncture	8°C and 25°C (46°F and 77°F) up to 12 hours prior to use	N/A	N/A	N/A
Storage: Punctured Vials	N/A	2°C and 25°C (36°F and 77°F) up to 12 hours	N/A	N/A	N/A	N/A

What to Do With 2023-2024 COVID-19 Products

- If you have any 23-24 COVID-19 vaccine in your units, remove them immediately as they are no longer authorized for use and should not be administered to patients
- If you find expired COVID-19 vaccines in your storage units that may have been administered to patients, please contact wachildhoodvaccines@doh.wa.gov or WAAdultVaccines@doh.wa.gov for guidance

Returning 2023-2024 COVID-19 Products

- Follow the [Returns Guide](#) and return all 2023-2024 COVID-19 vaccine (except punctured multi-dose vials) in the IIS
 - Adjust the doses out of your inventory using the category **Spoiled** and reason **Expired BUD** (**DO NOT** use the category “RECALL”)



Vaccine	Lot Number	Exp Date	Quantity on Hand	Physical Inventory	Adjustment (+/-)	Category	Reason
COVID-19, mRNA, LNP-S, PF, 25 mcg/0.25 mL (Moderna 6m-11y)	AU5550B	05/29/2024	8	5	-3.00	Spoiled	Expired BUD

- Moderna 2023-2024 vaccines ordered prior to the authorization of the 2024-2025 vaccines and that are currently in transit may arrive over the next 1-2 days
 - Providers should accept COVID-19 2023-2024 vaccine orders if they receive them post-FDA action
 - Providers should return these vaccines using the normal process for returning spoiled/expired vaccines in the IIS using the category **Spoiled** and reason **Expired BUD** (**DO NOT** use the category “RECALL”)


Temperature Monitoring

COVID-19 vaccine must be kept within certain temperature ranges. Acceptable temperatures are displayed below for each type of storage unit:

Storage Unit	Acceptable Range (F)	Acceptable Range (C)
Ultracold Freezer	-130° to -76° F	-90° to -60° C
Standard Freezer	-58° to +5° F	-50° to -15° C
Refrigerator	36° to 46° F	2° to 8° C

Temperature Excursion Guide

WASHINGTON STATE
Childhood Vaccine Program
 Office of Immunization | (360) 236-2829 | doh.wa.gov/cvp | wachildhoodvaccines@doh.wa.gov



Vaccine Temperature Excursion Guide

NOTIFY

Notify the primary or backup vaccine coordinator immediately if you discover a temperature excursion.

Bag the affected vaccines and place a label on them saying "DO NOT USE." Do not discard these vaccines or remove them from the storage unit.

DOCUMENT

Document the details of the temperature excursion including the:

- Date, time, and name of person completing report, description of the event, storage unit temperature, inventory vaccines affected
- Determine the length of time the vaccine has been out of range including any previous temp excursions

After manufacturer determination:

- Note date and length of time out of range on vaccine boxes
- Document the excursion via your REDCap portal including manufacturer determination and case number(s)/PDFs or emails of stability information

CONTACT

Contact the vaccine manufacturers. Be prepared to provide documentation and data logger information. Follow manufacturer guidance based on viability of vaccines. Record and save any case numbers or PDFs/emails of stability information.

If manufacturer guidance is unclear or states that providers can use their discretion to continue to use the vaccine, you must contact the DOH Childhood Vaccine Program at WACHildhoodVaccines@doh.wa.gov. Providers do not have the authority to discard publicly purchased vaccines.

Manufacturer Contact Numbers	
(Click links for online tools where available)	
AstraZeneca (Medimmune)	877-633-4411
Bavarian Nordic	844-422-8274
GlaxoSmithKline	888-825-5249
MassBiologics (Grifols)	617-474-3000
Merck	800-672-6372
Moderna	866-663-3762
Novavax	855-239-9174
Pfizer	800-438-1985
Sanofi Pasteur	800-822-2463
Seqirus	855-358-8966

CORRECT

Determine and address what caused the temperature issue. Check the basics, including the power supply, the unit door, and thermostat settings.

If the excursion was the result of a temperature fluctuation, follow guidance on adjusting the storage unit temperature to the correct range.

If the thermometer failed, implement your back-up thermometer. If the storage unit failed, implement your emergency plan.

If vaccines were moved to another unit please provide 3 days stable temps in range before moving vaccines back into unit.

Vaccine Storage

- Store each type of vaccine or diluent in its original packaging and in a separate container
- Ensure all inventories from CVP, AVP and Private Purchase vaccines are separated and clearly marked
- Place vaccines and diluents with the earliest expiration dates in front of those with later expiration dates-rotate your stock!



Beyond Use Date (BUD)

What is a Beyond Use Date (BUD)?

The Beyond Use Date (BUD) replaces the manufacturer's expiration date but never extends it—always use the earlier date when reviewing the two dates. The BUD should be noted on the label along with the initials of the person making the calculation. Do NOT use vaccine after the beyond-use date or expiration date, whichever comes first.

- Examples of when a COVID-19 vaccine may need a BUD include:
 - Moving vaccine from ultra-cold storage or standard freezer to refrigerator, or to room temp
 - Reconstituted vaccines
 - Multidose vials that are punctured
 - Manufacturer-shortened expiration dates
- Providers are required to label/clearly mark vaccine vials/boxes to indicate BUD.
- The [CDC](#) & [DOH POP Shop](#) have developed labels for this purpose; however, any method of tracking BUD is acceptable.
- CDC Trainings: [What is a Vaccine Beyond-Use Date?](#) & [Expiration Date & Beyond-Use Date](#)

Beyond Use Date(BUD) and Vaccine Loss



- Never change the expiration date for COVID-19 vaccines to the Beyond Use Date in the IIS
- When COVID-19 vaccine has an expired BUD date, remove the vaccine from your storage unit and adjust the doses out of your inventory using the category **Spoiled** and reason **Expired BUD**:
BUD:

Vaccine	Lot Number	Exp Date	Quantity on Hand	Physical Inventory	Adjustment (+/-)	Category	Reason
COVID-19, mRNA, LNP-S, PF, 25 mcg/0.25 mL (Moderna 6m-11y)	AU5550B	05/29/2024	8	5	-3.00	Spoiled	Expired BUD

- After reconciliation, providers should follow the [vaccine return](#) process. All COVID-19 vaccine loss (expired, spoiled and wasted) must now be accounted for in the IIS and all expired & spoiled vaccine must be returned (except punctured multi-dose vials)
- Vaccine Loss Logs don't need to be submitted for COVID loss due to expired BUD or expired vaccine only


2024-2025 State-Supplied COVID-19 Vaccines

Moderna COVID-19 Vaccines

Pediatric 6 months-11 years	Adolescent 12+/Adult Pre-Filled Syringe (Spikevax)
 <p>Green Label</p>	 <p>Blue Label</p>
2024-2025 Formula	2024-2025 Formula

- Can be stored in a regular freezer until expiration
- All vaccine moved from a regular freezer to refrigerator now has up to a **60-day** Beyond Use Date
- To avoid waste, store vaccine in the freezer and thaw doses in the fridge as needed

Moderna Beyond Use Date Labels




Washington State Department of
HEALTH

MODERNA
COVID-19 Vaccine Cold Storage

Freezer / Refrigerator

Lot #: _____

Beyond Use-By Date: _____



MODERNA COVID-19 Vaccine WA STATE DEPT OF HEALTH

Lot number(s): _____



Time Punctured: _____ Today's Date: _____

Use by Time: _____ Use by Date: _____

- ✓ All Moderna vaccines that are moved from a regular freezer to the refrigerator have up to a 60-day Beyond Use Date

Pfizer COVID-19 Vaccines

Ultra-Cold Storage or Refrigerator (with BUD): Refrigerator:

Infant/Toddler 6 months-4 years	Pediatric 5-11 years
	
2024-2025 Formula	2024-2025 Formula

- Can be stored in an ultra-cold freezer until expiration
- **Do not store in regular freezer**
- All vaccine moved from an ultra-cold freezer to refrigerator has up to a **10-week** Beyond Use Date (BUD)
- To avoid waste with multi-dose vials, store vaccine in the ultra-cold freezer and thaw doses in the fridge as needed

Adolescent 12+/Adult Pre-Filled Syringe (Comirnaty)

2024-2025 Formula

- Store in refrigerator until expiration
- **Does not ship with temperature monitor**


Ultra Cold Storage Considerations

- Use a DDL with an air probe or probe designed specifically for ultra cold temperatures
- Use the Ultra-Cold Temperature Monitoring Log to record temperatures [Fahrenheit](#) & [Celsius](#)

ULTRA COLD TEMPERATURE MONITORING LOG: Days 1-15 (CELSIUS)																							
CLINIC NAME: _____								PROVIDER PIN: _____															
FREEZER NAME/NUMBER: _____								MONTH & YEAR: _____															
INSTRUCTIONS ON RECORDING TEMPERATURES - OPTION 1 (PREFERRED) (MIN/MAX): 1. Enter Provider information above and write your initials below in "Staff Initials". 2. Note the time below in "Exact Time". 3. Record min/max temperatures at the start of each workday under the appropriate date.								INSTRUCTIONS ON RECORDING TEMPERATURES - OPTION 2 (CURRENT TEMP): 1. Record current temps twice, at beginning and end of each workday. 2. Put an "X" in the row that corresponds to the refrigerator's temperature. 3. If any out-of-range temp, see instructions to the right.								Take action if temperature is out of range - too warm (above -60°C) or too cold (below -90°C): 1. Label exposed vaccine "do not use," and store it under proper conditions as quickly as possible. 2. Do not discard vaccines unless directed to by the manufacturer(s) and/or your state health department. 3. Record the out-of-range temps and the room temp in the "Action" area on the bottom of the log. 4. Notify your vaccine coordinator and follow the Vaccine Temperature Excursion Guide. 5. For more information, visit: www.doh.wa.gov/CVP > Storage and Handling							
Day of Month																							
Min/Max Temp																							
Refrigerator																							
Exact Time of Temp																							
Room Temp																							
Staff Initials																							
<div style="display: flex; justify-content: space-between;"> > -60°C WARNING TOO WARM DANGER!!! WARNING TOO WARM </div>																							
-60°C																							
-61°C																							
-62°C																							
-63°C																							
-64°C																							
-65°C																							
-66°C																							
-67°C																							
-68°C																							
-69°C to -90°C																							
<div style="display: flex; justify-content: space-between;"> < -90°C WARNING TOO COLD DANGER!!! Call the manufacturer for vaccine viability WARNING TOO COLD </div>																							
Action Please list steps taken to address temperature/storage unit issues. Include manufacturer's determination and case number(s).																							
DATE: / / C: °C i.e., Action Taken: Fridge control adjusted, contacted manufacturers- vaccine viable, case #123456																							

DOH 348-988 September 2023 To request this document in another format, call 1-800-525-0127. Deaf or hard of hearing customers, please call 711 (Washington Relay) or email civilrights@doh.wa.gov.

Pfizer Beyond Use Date Labels




Washington State Department of
HEALTH

PFIZER
COVID-19 Vaccine Cold Storage

Ultra Cold Freezer / Refrigerator

Lot #: _____

Beyond Use-By Date: _____



PFIZER COVID-19 Vaccine WA STATE DEPT OF HEALTH

Lot number(s): _____

Time Punctured: _____ Today's Date: _____


Use by Time: _____ Use by Date: _____

- ✓ Reminder: Pfizer 12+ pre-filled syringes can be stored in the refrigerator until expiration and do not need a Beyond Use Date label

Novavax COVID-19 Vaccine

(Pending FDA Authorization)

Refrigerator:



- ✓ This vaccine is only stored in the refrigerator, so no beyond use date label is needed

Storage Unit	Pfizer-BioNTech	Moderna	Novavax (Pending FDA authorization)
Ultra-Cold	Until Expiration: Pediatric Formulations <ul style="list-style-type: none"> • Single-Dose Vial (5-11 years) • Multi-Dose Vial (6 months-4 years) 	No	No
Freezer	No	Until Expiration: Prefilled Syringes <ul style="list-style-type: none"> • Adolescent/Adult (Spikevax 12+ years) • Pediatric (6 months-11 years) 	No
Refrigerator	Until Expiration: <ul style="list-style-type: none"> • Adolescent/Adult Pre-filled Syringe (Comirnaty 12+ years) • Diluent (for 6 months-4 years only) Beyond Use Dates (up to 10 weeks): Pediatric Formulations <ul style="list-style-type: none"> • Single-Dose Vial (5-11 years) • Multi-Dose Vial (6 months-4 years) 	Beyond Use Date (up to 60 days): Prefilled Syringes <ul style="list-style-type: none"> • Adolescent/Adult (Spikevax 12+ years) • Pediatric (6 months-11 years) 	Until Expiration

When to Ask for Assistance

Please reach out to DOH for Storage & Handling support if:

- Pfizer or Novavax vaccine is discovered in a regular freezer
- Pfizer pre-filled syringes are found in an ultra-cold or regular freezer
- Moderna or Novavax vaccine is found in ultra-cold storage unit
- A Beyond Use Date (BUD) wasn't noted on vaccine moved from an ultra-cold or regular freezer to refrigerator
- Expired and past BUD COVID-19 vaccine was administered to patients

Knowledge Check

True or false:

You must have an ultra-cold freezer to order COVID-19 vaccine.

Knowledge Check

Answer: False

All COVID-19 vaccine can be stored in the refrigerator. You can order the amount of vaccine you think you will be able to use in the following storage scenarios:

- Ultra-cold presentations of Pfizer COVID-19 vaccine (vials) can be stored in a fridge for up to 10 weeks with BUD label
- Moderna COVID-19 vaccine can be stored in a fridge for up to 60 days with BUD label
- Pfizer prefilled syringes of COVID-19 (12+ years) vaccine and Novavax prefilled syringes (12 years+) are always stored in the fridge until expiration

Ordering

- Ordering for all 2023-2024 COVID-19 vaccines has been turned off in the IIS
- There is no need to stockpile vaccine at the beginning of the season, supply should be steady throughout the year

Ordering Tips

- Consider the type of storage units you have before choosing which product/quantity to order
- Look at vaccines administered at the same time last year to estimate demand
- Only order quantities that you will be able to use before expiration
 - Place smaller, more frequent orders to avoid excessive loss
 - You can always order outside your monthly window; please order as frequently as needed
- Most products are available to order in minimum quantities of 10
One exception is the Pfizer 3-dose, multi-dose vial which is available in a minimum order quantity of 30

COVID-19 Vaccine Loss

September 24, 2023-August 23, 2024

Program	Total COVID-19 Doses Distributed	Total Number of COVID-19 Doses Expired/Spoiled/Wasted	% Vaccine Loss Based on Doses Distributed	COVID-19 Wastage Cost
Childhood Vaccine Program (CVP)	210,230	58,596	28%	\$4,442,296
Adult Vaccine Program (AVP)	15,220	3,979	26%	\$321,417

Adult Vaccine Program (AVP)

AVP COVID-19 Vaccine Availability

The Adult Vaccine Program received an additional ~1 million dollars for COVID-19 vaccine purchase for adults.

- All enrolled AVP providers will have the option to order COVID-19 vaccine
- AVP COVID-19 vaccine can be administered to both uninsured and underinsured adults. **(All other AVP vaccine can only be administered to uninsured adults)**
- Moderna, Pfizer, and Novavax products will be available for request
- Providers who enroll after AVP's 7/31 enrollment deadline will have the option to order COVID-19 vaccine and will receive a COVID-19 vaccine order set in the IIS.
- We will send out an additional newsletter communication when AVP COVID ordering is open in the IIS.

AVP COVID-19 Ordering Process

- Vaccine orders submitted to DOH will be processed weekly according to the pro-rata allocation plan by county and reserved groups
- The goal is to maximize the number of providers receiving some doses
- Consideration will be given to provider's vaccine prioritization, number of uninsured patients served, previous ordering history and usage, existing inventory, and extenuating circumstances
- Providers must be up to date on temperature logs in REDCap and Inventory reporting in the IIS in order to receive an allocation

Knowledge Check

True or False:

COVID-19 requests will be approved for an allocation as long as a provider is enrolled in AVP and there is available supply.

Knowledge Check

Answer: False

- Providers must also be compliant with accountability requirements to receive an allocation. This includes monthly temperature log submission in REDCap and inventory report submission in the IIS.

Resources

- [Adult Vaccine Program](#) (DOH), contact WAAdultVaccines@doh.wa.gov
- [Childhood Vaccine Program](#) (DOH), contact WACHildhoodVaccines@doh.wa.gov
- [2024-2025 State Supplied COVID-19 Vaccines At-a-Glance](#) (DOH)
- [Vaccine Return Guide](#) (DOH)
- [Storage and Handling Summary Documents + BUD Labels](#) (CDC)
- [POP Shop BUD Labels](#) (DOH)
- [Vaccine Storage and Handling Toolkit](#) (CDC)
- [Vaccine Temperature Excursion Guide](#) (DOH)
- Training Links:
 - [The Difference Between a Vaccine Expiration Date and Beyond-Use Date or Time](#) (TRAIN.org)
 - [What is a Vaccine Beyond-Use Date or Time?](#) (TRAIN.org)

Obtaining Continuing Education

- Continuing education credit is available for nurses and medical assistants
- There is no cost for CEs
- Expiration date is 11/29/24
- Successful completion of this continuing education activity includes the following:
 - Attending the entire live webinar or watching the webinar recording, and completing the evaluation
 - **On the evaluation, please specify which type of continuing education you wish to obtain**
- **Please note:** CE certificates are NOT generated after evaluation completion—CE certificates will be sent by DOH via email within a few weeks after evaluation completion
- If you have any questions about CEs, contact Trang Kuss at trang.kuss@doh.wa.gov





To request this document in another format, call 1-800-525-0127. Deaf or hard of hearing customers, please call 711 (Washington Relay) or email civil.rights@doh.wa.gov.